ASCO® 2024 Insights: "INAVO-PBO Trial - 1L Inavolisib/Placebo + Palbo + Fulv in Patients With PIK3CAm, HR+/HER2‑ Locally Advanced/Metastatic BC Who Relapsed During/Within 12 Months of Adjuvant ET Completion"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "INAVO-PBO Trial - 1L Inavolisib/Placebo + Palbo + Fulv in Patients With PIK3CAm, HR+/HER2‑ Locally Advanced/Metastatic BC Who Relapsed During/Within 12 Months of Adjuvant ET Completion"

By ecancer FEATURING Dejan Juric

106 views

July 2, 2024

0 Comments

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

24:36

2024 ASCO® Annual Meeting Insights Hub

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

Feat. S. Aithal

09:34

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical …

Feat. M. Lipsyc-Sharf

05:06

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Genomic Alterations in HR+/HER2- Metastat…

Feat. M. Bhave

View All

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo

12:14

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

Feat. P. Tarantino

11:31

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino

12:35

Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo

07:23

Total Health

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Feat. R. O'Regan

03:40

Integrity CE

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & …

Feat. A. Bardia

14:16

Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino

09:55

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton

17:39

Yale School of Medicine

2023 Menopause Update

Feat. M. Minkin

10:53

Kirollos Hanna

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

28:36

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri

05:43

Total Health

Neoadjuvant Chemo for HR+ BC: Year in Review

Feat. C. Ma

17:20

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino

57:44

Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl

17:50

AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde

27:01

Scripps Health

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Feat. S. Sammons

22:34

Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney

10:34

Sara Tolaney

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Feat. H. Rugo

36:18

Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Feat. H. Rugo

27:04

Fengting Yan

Login

Login

Join VuMedi

ASCO® 2024 Insights: "INAVO-PBO Trial - 1L Inavolisib/Placebo + Palbo + Fulv in Patients With PIK3CAm, HR+/HER2‑ Locally Advanced/Metastatic BC Who Relapsed During/Within 12 Months of Adjuvant ET Completion"

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

Related Content